Longboard Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
September 29 2022 - 4:01PM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that Kevin Lind, Longboard’s President & CEO, will participate
in a panel discussion at the Cantor Neurology & Psychiatry
Conference, which is taking place October 6-7, 2022, in San
Francisco, CA.
Presentation
Details:Panel Title: Next generation
drugs, new targets and innovative approaches for high-unmet need
epileptic disorders Date/Time: October 6, 2022, at
4:20 PM ET (1:20 PM PT) in Track 2Please note, this presentation
will be available to registered conference attendees only. Please
reach out to your Cantor representative for additional detail or to
arrange a meeting with management.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with
negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes,
in development for the potential treatment of seizures associated
with a broad range of developmental and epileptic encephalopathies.
Longboard is also evaluating LP659, a centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
in development for the potential treatment of multiple neurological
diseases, and LP143, a centrally acting, full cannabinoid type 2
receptor (CB2) agonist, in development for the potential treatment
of central nervous system (CNS) diseases and disorders.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Longboard’s
participation in the upcoming conference, Longboard’s clinical and
preclinical programs, ability to develop and deliver medicines, and
focus. For such statements, Longboard claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Longboard’s expectations.
Factors that could cause actual results to differ materially from
those stated or implied by Longboard’s forward-looking statements
are disclosed in Longboard’s filings with the Securities and
Exchange Commission (SEC). These forward-looking statements
represent Longboard’s judgment as of the time of this release.
Longboard disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024